Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

13.40 +0.44 (+3.40%)
Streaming Delayed Price Updated: 3:51 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 436,526
Open 13.12
Bid (Size) 13.40 (6)
Ask (Size) 13.41 (1)
Prev. Close 12.96
Today's Range 12.87 - 13.53
52wk Range 7.300 - 16.32
Shares Outstanding 34,233,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategy 
From Metagenomi, Inc.
Via GlobeNewswire

Performance

YTD
+51.2%
+51.2%
1 Month
-15.2%
-15.2%
3 Month
+17.3%
+17.3%
6 Month
+25.9%
+25.9%
1 Year
+6.5%
+6.5%

More News

Read More
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday
Via Benzinga
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated
Via Stocktwits
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
Via Benzinga
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
From KalVista Pharmaceuticals, Inc.
Via Business Wire
How KalVista Pharma Is Taking On A Rare But Deadly Disease
Via Investor's Business Daily
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
From KalVista Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?
KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market
What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?
The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 13.40
When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 08/22/25 03:51 PM ET
What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?
The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 458.73M
How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?
KalVista Pharmaceuticals, Inc. - Common Stock has 459M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.